
-
Biomea Fusion NasdaqGS:BMEA Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Location: 900 Middlefield Road, Redwood City, CA, 94063, United States | Website: https://biomeafusion.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
28.05M
Cash
35.86M
Avg Qtr Burn
-28.38M
Short % of Float
34.95%
Insider Ownership
14.81%
Institutional Own.
56.55%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BMF-219 (icovamenib) Details Type 2 diabetes | Phase 2b Update | |
Phase 2 Data readout | ||
Phase 2 Initiation | ||
BMF-500 Details Leukemia | Phase 1 Update | |
BMF-219 (icovamenib) Details Acute myeloid leukemia, Acute lymphoblastic leukemia | Failed Discontinued | |
BMF-219 (icovamenib) Details Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma | Failed Discontinued |